7 completed. 7 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
| Phase 2 | 5 | Completed 5 |
Follow Deafness: new trials by email Literature Review of Deafness trials Research Report on Deafness
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss PIPE-505, Placebo - Sensorineural Hearing Loss | Phase 1 / Phase 2 | Completed | Contineum Therapeutics | 28 | 2020-10-15 | 2025-04-01 |
| Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome NPI-001, Placebo - Usher Syndromes | Phase 1 / Phase 2 | Completed | Nacuity Pharmaceuticals, Inc. | 49 | 2020-09-03 | 2026-07-01 |
| Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene QR-421a, Sham-procedure (dose cohort 1&2 only) - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 1 / Phase 2 | Completed | ProQR Therapeutics | 20 | 2019-03-06 | 2022-04-20 |
| A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome dantrolene sodium - Wolfram Syndrome, Diabetes Mellitus | Phase 1 / Phase 2 | Completed | Washington University School of Medicine | 21 | 2017-01-01 | 2024-03-13 |
| A Safety Study of the Auditory Brainstem Implant for Pediatric Profoundly Deaf Patients Auditory Brainstem Implant - Profound Bilateral Deafness Due to, Bilateral Cochlear Aplasia | Phase 1 | Completed | Laurie Eisenberg | 10 | 2014-03-01 | 2025-09-15 |
| Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss Ancrod, Saline solution - Hearing Loss, Deafness | Phase 1 / Phase 2 | Completed | Nordmark Arzneimittel GmbH & Co. KG | 31 | 2013-05-01 | 2018-12-21 |
| Outcomes In Children With Developmental Delay And Deafness cochlear implantation, hearing aids - Deafness, Hearing Loss | Phase 1 | Completed | Stanford University | 303 | 2009-09-01 | 2016-11-15 |
Hearing Loss (3) · Hearing Loss, Sensorineural (2) · Usher Syndromes (2) · Ataxia (1) · Diabetes Mellitus (1) · Ear Diseases (1) · Eye Abnormalities (1) · Eye Diseases (1) · Eye Diseases, Hereditary (1) · Hearing Disorders (1) · Hearing Loss, Hidden (1) · Intellectual Disability (1) · Learning Disabilities (1) · Optic Atrophy (1)
Nervous System Diseases (7) · Neurologic Manifestations (7) · Otorhinolaryngologic Diseases (7) · Pathological Conditions, Signs and Symptoms (7) · Sensation Disorders (7) · Signs and Symptoms (7) · Ear Diseases (6) · Hearing Disorders (6) · Hearing Loss (4) · Abnormalities, Multiple (3) · Blindness (3) · Congenital Abnormalities (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Deaf-Blind Disorders (3)
Ancrod (1) · Auditory Brain Stem Implants (1) · Cochlear Implantation (1) · Dantrolene (1) · Hearing Aids (1) · Intravitreal Injections (1) · Saline Solution (1)
Contineum Therapeutics (1) · Laurie Eisenberg (1) · Nacuity Pharmaceuticals, Inc. (1) · Nordmark Arzneimittel GmbH & Co. KG (1) · ProQR Therapeutics (1) · Stanford University (1) · Washington University School of Medicine (1)
United States (5) · Australia (1) · Canada (1) · Czechia (1) · France (1) · Germany (1)
Eric Wilkinson, MD (1) · Fumihiko Urano, MD (1) · John Oghalai (1) · Laurie S. Eisenberg, PhD (1) · Lee Anderson, MD (1) · Martin Canis, MD PhD (1) · Stephen Huhn, MD (1)
PMID 26366332, PMID 27898605, PMID 29714549, PMID 29718280, PMID 31215818, PMID 34185708, PMID 35607935, PMID 37418643
2018 (1), R01DC010075 (1), R21DK113487 (1)